Lymphomas | Clinical

Incorporating Genomics into Lymphoma Classification Can Improve Care

November 21, 2020

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.

FDA Postpones Review of BLA for Liso-Cel in R/R Large B-Cell Lymphoma

November 16, 2020

The FDA will not complete its review of the Biologics License Application for lisocabtagene maraleucel for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 prior lines of therapy by the Prescription Drug User Fee Act action date of November 16, 2020.

In Low-Grade Follicular Lymphoma, Expert Weighs Frontline Options

November 04, 2020

A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.

Targeted Therapies Offer New Treatment Options for R/R MZL Across Subtypes

October 10, 2020

Marginal zone lymphomas are a heterogenous group of B-cell non-Hodgkin lymphomas based on their etiology and clinical presentation, and as such, treatment for these diseases vary by subtype, according to Stephen Douglas Smith, MD.

Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk

October 10, 2020

When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.